GlaxoSmithKline PLC
19 September 2001
LETTER TO COMPANY ANNOUNCEMENTS OFFICE
Directors' Interests
I give below details of changes in directors' interests in the Ordinary Shares
of GlaxoSmithKline plc.
14 September 2001 The Administrators of the SmithKline Beecham Employee Share
Ownership Trust ('the ESOT') notified the Company on the 18
September 2001, that 35,209 Ordinary shares had been
transferred from the ESOT to participants of the SmithKline
Beecham 1991 Share Option Plan and that 1,746 Ordinary
shares had been transferred from the ESOT to participants of
the SmithKline Beecham Bonus Investment Plan. The trust also
purchased 48 Ordinary shares at a price of £17.48 per share
for participants of the SmithKline Beecham Unapproved Share
Matching Plan.
The ESOT is a discretionary fund of which all employees or former employees of
SmithKline Beecham plc and its subsidiaries are potential beneficiaries. One of
the Company's directors, Dr J P Garnier is therefore, interested in the shares
held in the fund from time to time in the same way as other employees or former
employees of SmithKline Beecham plc and its subsidiaries.
S M Bicknell
Company Secretary
FROM GLAXOSMITHKLINE PLC
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.